News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Paolo Tarantino: More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i
Photo taken from Paolo Tarantino/Twitter
Nov 19, 2023, 17:20

Paolo Tarantino: More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i

Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter:

“Capivasertib is now approved in combo with fulvestrant for pts with pretreated ER+/HER2- MBC whose tumor has an alteration in PIK3CA, AKT1 or PTEN (approx 40%).

More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i.”

For more information click here.
Source: Paolo Tarantino/Twitter

cancer Capivasertib OncoDaily Oncology Paolo Tarantino
Special Coverage
Voices
Sep 7, 2025, 05:55
Chalothorn Wannaphut: Presenting at SOHO2025
Voices
Sep 7, 2025, 05:46
John McGrane: Everything You Need to Know About Biliary Tract Cancers
Voices
Sep 7, 2025, 05:24
Christian Rolfo: Amazing IASLC Academy 2025!
Voices
Sep 7, 2025, 05:18
Shreyas Kalantri: Two of My Posters Are Being Presented at WCLC25
Voices
Sep 7, 2025, 05:14
30 Days Until the Jimmy Fund Walk 2025 - Florez Lab
Voices
Sep 7, 2025, 05:09
Roberto Borea: Umberto Malapelle Opens the Plenary at WCLC25
Voices
Sep 7, 2025, 05:05
Rita Ahmad: Sharing Exciting Updates on Immunotherapy in IBCL
Voices
Sep 7, 2025, 04:54
Herbert Loong: The ASCO International Affairs Committee 2025-26
Voices
Sep 7, 2025, 04:53
Luis E. Raez: Very Successful IASLC Latin America Session at WCLC25
Science
Sep 7, 2025, 04:45
Iannis Aifantis: The pre-T Cell Receptor as an Immunotherapy Target in T Cell Leukemia
Voices
Sep 7, 2025, 04:42
Estela Rodriguez Shared Insights on Day 1 of WCLC25
Voices
Sep 7, 2025, 04:32
Elizabeth Mittendorf: Important Discussions on Collaboration to Address the Global Burden of Cancer